Atopic Dermatitis

Brexogen Inc.’s exosome therapy is the first entry of a clinical trial of exosome treatment for atopic dermatitis.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, talk about the use of oral systemic agents and what they’ve learned about the patient experience from the use of these agents.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, examine the clinical context for the approval of topical ruxolitinib and its role in the treatment armamentarium.

Recent studies show patients are experiencing adverse effects of stopping corticosteroid treatment.

Thought leaders discuss why JAK inhibitors are well suited for the management of itch and inflammation in the treatment of moderate to severe atopic dermatitis.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, review the recent trajectory of the atopic dermatitis therapeutic spectrum, notably how several newer approvals have changed how clinicians approach treatment.

At the 2022 Fall Clinical Dermatology Conference, one clinician discusses history, definitions, and diagnosis for this common skin affliction.

Lisa Swanson, MD, FAAD, and James Q. Del Rosso, DO, FAOCD, FAAD, gave an in-depth discussion on Janus kinase (JAK) inhibitors for the management of atopic dermatitis at the 2022 Fall Clinical Dermatology Conference.

Alphyn Biologics’ study of AB-101a also evaluates patients who suffer from bacterial infections associated with atopic dermatitis.

In this episode, Jeffrey M. Cohen, MD, a board-certified medical dermatologist and the director of the Psoriasis Treatment Program at the Yale School of Medicine, discusses treatment options for adolescents with atopic dermatitis, how the changing seasons can affect flare-ups, and what caregivers can do at home to help prevent extreme itching.